Syros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per Share

Brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.57) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.75) and the highest is ($0.49). Syros Pharmaceuticals reported earnings per share of ($0.48) in the same quarter last year, which would indicate a negative year over year growth rate of 18.8%. The company is scheduled to announce its next earnings report on Thursday, May 9th.

On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($2.29) to ($1.95). For the next fiscal year, analysts forecast that the business will post earnings of ($2.14) per share, with EPS estimates ranging from ($2.41) to ($1.87). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, March 7th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.05). Syros Pharmaceuticals had a negative return on equity of 64.43% and a negative net margin of 3,038.00%. The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $0.40 million.

Several research firms recently commented on SYRS. BidaskClub upgraded Syros Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 22nd. JMP Securities restated a “mkt outperform” rating and set a $18.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. HC Wainwright restated a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. Oppenheimer set a $13.00 target price on Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 7th. Finally, Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, December 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $15.29.

In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $7.83, for a total transaction of $1,311,548.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.80% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after purchasing an additional 11,711 shares during the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Syros Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after acquiring an additional 7,230 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock valued at $181,000 after acquiring an additional 10,995 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Syros Pharmaceuticals by 10.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock valued at $925,000 after acquiring an additional 7,062 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in shares of Syros Pharmaceuticals by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 77,768 shares of the company’s stock valued at $433,000 after acquiring an additional 18,215 shares during the last quarter. 67.87% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals stock traded up $0.43 during midday trading on Monday, hitting $9.14. 72,180 shares of the company’s stock were exchanged, compared to its average volume of 160,537. Syros Pharmaceuticals has a 52-week low of $5.17 and a 52-week high of $13.86. The stock has a market cap of $285.40 million, a price-to-earnings ratio of -4.79 and a beta of 1.22.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Story: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.